These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37450172)

  • 1. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
    Kang C; Blair HA
    Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Bar-Or A; Wiendl H; Montalban X; Alvarez E; Davydovskaya M; Delgado SR; Evdoshenko EP; Giedraitiene N; Gross-Paju K; Haldre S; Herrman CE; Izquierdo G; Karelis G; Leutmezer F; Mares M; Meca-Lallana JE; Mickeviciene D; Nicholas J; Robertson DS; Sazonov DV; Sharlin K; Sundaram B; Totolyan N; Vachova M; Valis M; Bagger M; Häring DA; Ludwig I; Willi R; Zalesak M; Su W; Merschhemke M; Fox EJ
    Mult Scler; 2022 May; 28(6):910-924. PubMed ID: 34605319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Williams MJ; Amezcua L; Cohan SL; Cohen JA; Delgado SR; Hua LH; Lucassen EB; Piccolo RS; Koulouris CR; Stankiewicz J
    Neurology; 2024 Aug; 103(3):e209610. PubMed ID: 39018512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
    Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L
    Mult Scler; 2022 Sep; 28(10):1562-1575. PubMed ID: 35266417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
    Kramer J; Linker R; Paling D; Czaplinski A; Hoffmann O; Yong VW; Barker N; Ross AP; Lucassen E; Gufran M; Hu X; Zielman R; Seifer G; Vermersch P
    Mult Scler J Exp Transl Clin; 2023; 9(4):20552173231203816. PubMed ID: 37829441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
    Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
    J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
    Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
    Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.
    Craner M; Al Malik Y; Babtain FA; Alshamrani F; Alkhawajah MM; Alfugham N; Al-Yafeai RH; Aljarallah S; Makkawi S; Qureshi S; Ziehn M; Wahba H
    Neurol Ther; 2022 Dec; 11(4):1457-1473. PubMed ID: 36048334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
    Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC
    Front Immunol; 2022; 13():814064. PubMed ID: 35967378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
    Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J
    Front Immunol; 2022; 13():852563. PubMed ID: 35432382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Kira JI; Nakahara J; Sazonov DV; Kurosawa T; Tsumiyama I; Willi R; Zalesak M; Pingili R; Häring DA; Ramanathan K; Kieseier BC; Merschhemke M; Su W; Saida T
    Mult Scler; 2022 Jul; 28(8):1229-1238. PubMed ID: 34787005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
    Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
    Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
    Yu H; Graham G; David OJ; Kahn JM; Savelieva M; Pigeolet E; Das Gupta A; Pingili R; Willi R; Ramanathan K; Kieseier BC; Häring DA; Bagger M; Soelberg Sørensen P
    CNS Drugs; 2022 Mar; 36(3):283-300. PubMed ID: 35233753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.